Physician

Raphael I. Kieval, MD

According to 2025 Medicare claims, Raphael Kieval, MD (NPI: 1730155029) practices rheumatology in the Boston, MA market, with the plurality of this provider's patient population coming from Plymouth, MA. This provider's primary affiliated billing organization is AMERICAN ARTHRITIS & RHEUMATOLOGY ASSOCIATES MA PC (NPI: 1164041349; TIN: 84-4319867) and primary practice location at 02301-7153. Kieval is affiliated with the BMC Integrated Care Services, Inc. (ACO ID: A2666), participating under the MSSP model.

Kieval's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 885 traditional Medicare patients, billed 166,145 HCPCS/CPT codes, and received $1,817,483 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 9,907 prescription claims across 1,039 beneficiaries totaling $7,168,370 in drug costs, led by Enbrel Sureclick (Etanercept). DME data shows 15 claims. Open Payments data shows 223 records totaling $29,446. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $438,708 to $1,817,483. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,353,246 to $7,168,370. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	710	28,525	$438,708
2016	716	49,226	$585,436
2017	733	60,885	$726,245
2018	797	85,739	$1,100,765
2019	824	92,558	$1,261,127
2020	925	104,446	$1,660,633
2021	920	109,723	$1,479,648
2022	979	141,293	$1,726,050
2023	923	148,916	$1,712,324
2024	885	166,145	$1,817,483

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	702	7,041	$1,353,246
2016	752	7,367	$1,443,230
2017	725	7,459	$1,858,991
2018	933	9,491	$2,870,374
2019	898	9,247	$3,093,440
2020	859	9,175	$3,423,403
2021	977	9,451	$4,450,700
2022	1,072	10,114	$6,192,770
2023	1,029	10,181	$6,630,775
2024	1,039	9,907	$7,168,370

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	24	25	$1,320
2016	N/R	N/R	N/R
2017	25	25	$1,889
2018	N/R	11	$932
2019	27	27	$2,594
2020	N/R	N/R	N/R
2021	12	12	$1,199
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	15	15	$1,547

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	401	641	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	389	566	$65
96401	Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle	170	571	$54
J0897	Injection, denosumab, 1 mg	132	12,480	$20
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	347	549	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Enbrel Sureclick	Etanercept	169	5,238	$1,379,492
Humira(Cf) Pen	Adalimumab	163	4,576	$1,270,026
Rinvoq	Upadacitinib	106	3,180	$680,171
Xeljanz Xr	Tofacitinib Citrate	100	3,180	$620,271
Humira Pen	Adalimumab	63	1,764	$439,399

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L3924	Hand finger orthosis, without joints, may include soft interface, straps, prefabricated, off-the-shelf	N	15	15	$1,547

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	223	$29,446	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Raphael I. Kieval, MD?

Tedicare shows public-source Medicare data for Raphael I. Kieval, MD (NPI 1730155029), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Raphael I. Kieval, MD have ACO affiliation data?

Raphael I. Kieval, MD is shown with ACO affiliation data for BMC Integrated Care Services, Inc. (MSSP, ACO ID A2666).

What billing organization is linked to Raphael I. Kieval, MD?

Raphael I. Kieval, MD is linked to AMERICAN ARTHRITIS & RHEUMATOLOGY ASSOCIATES MA PC (billing NPI 1164041349) in the available physician profile data.

Does Raphael I. Kieval, MD have Open Payments data?

Raphael I. Kieval, MD has 223 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.